Compare · DWTX vs NVO
DWTX vs NVO
Side-by-side comparison of Dogwood Therapeutics Inc. (DWTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DWTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 3730.3x DWTX ($49.1M).
- Over the past year, DWTX is down 68.6% and NVO is down 45.7% - NVO leads by 22.9 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 1 for DWTX).
- NVO has more recent analyst coverage (25 ratings vs 0 for DWTX).
- Company
- Dogwood Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $1.50-8.54%
- $41.01-4.51%
- Market cap
- $49.1M
- $183.15B
- 1M return
- -5.66%
- -10.44%
- 1Y return
- -68.55%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 1
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DWTX
- Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
- SEC Form SCHEDULE 13G filed by Dogwood Therapeutics Inc.
- SEC Form 10-Q filed by Dogwood Therapeutics Inc.
- Dogwood Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dogwood Therapeutics Announces First Quarter 2026 Financial Results
- Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
- SEC Form DEF 14A filed by Dogwood Therapeutics Inc.
- Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
- SEC Form PRE 14A filed by Dogwood Therapeutics Inc.
- Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care